住友 誠

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 81%
3. Neprilysin 41%
4. Neoplasms 32%
5. Nephrectomy 25%
6. Prostatectomy 23%
7. Neoplasm Metastasis 23%
8. Kidney Neoplasms 23%
9. Prostate-Specific Antigen 21%
10. Urinary Bladder Neoplasms 20%
11. Androgens 19%
12. Prostate 19%
13. Recurrence 18%
14. Topotecan 17%
15. Cystectomy 17%
16. Castration 16%
17. Kidney 15%
18. cabazitaxel 14%
19. Nephroureterectomy 14%
20. Therapeutics 14%
21. Growth 14%
22. Urinary Bladder 13%
23. Vorinostat 13%
24. Androgen Receptors 12%
25. Survivin 12%
26. Apoptosis 12%
27. Survival 12%
28. Prostatitis 11%
29. Ureter 11%
30. Gefitinib 11%
31. Adrenalectomy 11%
32. Carcinoma 11%
33. Bladder Diverticulum 9%
34. Orchiectomy 9%
35. Transurethral Resection of Prostate 9%
36. Groin 9%
37. Protein Kinase C 8%
38. Molecular Targeted Therapy 8%
39. Testis 8%
40. Urinary Catheters 8%
41. Bombesin 8%
42. Urethral Stricture 8%
43. Serum 8%
44. Deep Learning 8%
45. Diverticulum 8%
46. Neuropeptides 8%
47. Fatty Acid Synthases 8%
48. Robotics 8%
49. Tomography 8%
50. Docetaxel 8%